Skip to content
On July 20, seven pharmaceutical companies announced the formation of a new international alliance to help prepare the world for the next pandemic – […]
INTREPID Alliance seeks 25 new pandemic-ready antivirals Read More »
Heart disease remains the leading cause of death in the United States. According to the American Heart Association (AHA), in 2020, cardiovascular disease (CVD)
In a big week for reauthorization of the Pandemic All Hazards and Preparedness Act (PAHPA), versions of the legislation were approved by a House
PAHPA legislation moves forward in Senate and House Read More »
With over 6 million unintended pregnancies in the U.S. each year and birth rates on the rise since 2021, making it easy to obtain
FDA approves first over-the-counter birth control pill Read More »
We see a great demand for effective therapies, particularly for conditions with limited treatment options. Transformative treatments, no matter how small, have the impact
3 things to know about the future of small molecule therapeutics Read More »
On July 17, Eli Lilly announced positive results from clinical trials of donanemab, the company’s candidate for the treatment of Alzheimer’s disease. The drug
Eli Lilly’s Alzheimer’s drug shows promise in slowing cognitive decline Read More »
In the latest bioscience victory over viruses, the Food and Drug Administration (FDA) on July 17 gave the first approval to a monoclonal antibody
FDA approves monoclonal antibody to protect infants from RSV Read More »
The challenge of preventing pharmacy benefit managers (PBMs) from driving up drug prices was front and center on Capitol Hill this week. Bipartisan legislation
Congress puts PBMs in the spotlight during a busy week on Capitol Hill Read More »
Sutro Biopharma, Inc., a clinical-stage drug discovery, development, and manufacturing company, has made significant advancements in the field of antibody-drug conjugates (ADCs). Their innovative
Sutro Biopharma in clinical stages for groundbreaking cancer treatment Read More »
With the deadly threat of drug-resistant infections increasing daily, we desperately need actions to address the broken commercial marketplace for novel antimicrobials—including the PASTEUR
Legislation to fight AMR superbugs is an urgent need, BIO member tells Senate hearing Read More »
